Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level

Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study

(2011) J.-Y. Park et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

(2009) O. M. Woodward et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations

(2009) Melanie Kolz et al.   PLoS Genetics

Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance

(2008) E Kis et al.   ANNALS OF THE RHEUMATIC DISEASES

The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

(2008) KA Kim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

(2008) Y Yamasaki et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

(2008) Petra Bohanec Grabar et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

(2008) Abbas Dehghan et al.   LANCET